2-(2-嘧啶基氨基)乙醇 | 1742-25-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-(2-嘧啶基氨基)乙醇
• 英文名称: 2-(2-Hydroxy-ethylamino)-pyrimidin
• 英文别名: 2-(2-hydroxyethyl)-aminopyrimidine；2-(Pyrimidin-2-ylamino)ethanol
• CAS: 1742-25-2
• 化学式: C₆H₉N₃O
• mdl: MFCD11117713
• 分子量: 139.157
• InChiKey: KTMJYEXQVZXYKE-UHFFFAOYSA-N

物化性质

• 熔点：
  78-79.5 °C
• 沸点：
  318.8±44.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  58
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2-嘧啶基氨基)乙醇 在 哌啶乙酸盐 、 sodium hydride 作用下， 以 甲苯 为溶剂， 反应 20.0h， 生成 5-[4-(2-(2-pyrimidinylamino)ethoxy)-benzylidene]-2,4-thiazolidinedione
  参考文献：
  名称：

  [[.omega.-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents

  摘要：

  A series of [(ureidoethoxy)benzyl]-2,4-thiazolidinediones and [[(heterocyclylamino)alkoxy]-benzyl]-2,4-thiazolidinediones was synthesized from the corresponding aldehydes. Compounds from the urea series, exemplified by 16, showed antihyperglycemic potency comparable with known agents of the type such as pioglitazone and troglitazone (CS-045). The benzoxazole 49, a cyclic analogue of 16, was a very potent enhancer of insulin sensitivity, and by modification of the aromatic heterocycle, an aminopyridine, 37, was identified as a lead compound from SAR studies. Evaluation of antihyperglycemic activity together with effects on blood hemoglobin content, to determine the therapeutic index, was performed in 8-day repeat administration studies in genetically obese C57 Bl/6 ob/ob mice. From these studies, BRL 49653 (37) has been selected, on the basis of antihyperglycemic potency combined with enhanced selectivity against reductions in blood hemoglobin content, for further evaluation.

  DOI：

  10.1021/jm00049a017
• 作为产物：
  描述：

  2-氯嘧啶 、 C.I.酸性橙108 以 水 为溶剂， 生成 2-(2-嘧啶基氨基)乙醇
  参考文献：
  名称：

  Compounds

  摘要：

  式(I)的化合物：##STR1##或其互变异构体，或其药学上可接受的盐，或其药学上可接受的溶剂化合物，其中：A.sup.1代表取代或未取代的芳香杂环基团；R.sup.1代表氢原子，烷基基团，酰基基团，芳基烷基基团，其中芳基部分可以是取代或未取代的，或取代或未取代的芳基基团；R.sup.2和R.sup.3各自代表氢，或R.sup.2和R.sup.3一起代表键；A.sup.2代表总共最多具有五个取代基的苯环；n代表范围为2至6的整数；含有这种化合物的药物组合物以及这种化合物和组合物在医学中的用途。

  公开号：

  US05232925A1

文献信息

• [EN] PYRROLOPYRIMIDINES<br/>[FR] PYRROLOPYRIMIDINES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009016132A1

  公开（公告）日：2009-02-05

  The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are polo-like kinase (PLKs) inhibitors useful for the treatment of disease states mediated by PLK, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumour growth, rheumatoid arthritis, restenosis and atherosclerosis.

  本发明涉及化合物或其药用盐，制备它们的方法，含有它们的药物组合物以及它们在治疗中的用途。该发明特别涉及一类极化样激酶（PLKs）抑制剂化合物，用于治疗由PLK介导的疾病状态，特别是PLK4，特别是在治疗涉及异常细胞增殖的病理过程中有用的化合物，如肿瘤生长、类风湿性关节炎、再狭窄和动脉粥样硬化。
• [EN] NOVEL ANTI-INFLAMMATORY AGENTS<br/>[FR] NOUVEAUX AGENTS ANTI-INFLAMMATOIRES
  申请人：RESVERLOGIX CORP

  公开号：WO2010123975A1

  公开（公告）日：2010-10-28

  Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.

  揭示了调节白细胞介素-6（IL-6）和/或血管细胞粘附分子-1（VCAM-1）的方法，以及治疗和/或预防心血管和炎症性疾病及相关疾病状态的方法，例如动脉粥样硬化、哮喘、关节炎、癌症、多发性硬化、牛皮癣和炎症性肠病以及自身免疫疾病，通过给予天然存在或合成的喹唑啉衍生物。该发明提供了新颖的合成喹唑啉化合物，以及包含这些化合物的药物组合物。
• TREATMENT OF DISEASES BY EPIGENETIC REGULATION
  申请人：McLure Kevin G.

  公开号：US20130281398A1

  公开（公告）日：2013-10-24

  The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

  本公开提供了抑制溴结构域和额外末端结构域（BET）蛋白的非天然存在的多酚化合物。所公开的组合物和方法可用于治疗和预防对BET抑制剂易感的疾病或疾病。
• Compounds
  申请人：Beecham Group p.l.c.

  公开号：US05232925A1

  公开（公告）日：1993-08-03

  Compounds of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.

  式(I)的化合物：##STR1##或其互变异构体，或其药学上可接受的盐，或其药学上可接受的溶剂化合物，其中：A.sup.1代表取代或未取代的芳香杂环基团；R.sup.1代表氢原子，烷基基团，酰基基团，芳基烷基基团，其中芳基部分可以是取代或未取代的，或取代或未取代的芳基基团；R.sup.2和R.sup.3各自代表氢，或R.sup.2和R.sup.3一起代表键；A.sup.2代表总共最多具有五个取代基的苯环；n代表范围为2至6的整数；含有这种化合物的药物组合物以及这种化合物和组合物在医学中的用途。
• [EN] AKT / PKB INHIBITORS<br/>[FR] INHIBITEURS D'AKT/PKB
  申请人：ALMAC DISCOVERY LTD

  公开号：WO2011055115A1

  公开（公告）日：2011-05-12

  The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.

  这项发明涉及一系列具有特定活性的化合物，作为丝氨酸-苏氨酸激酶AKT的抑制剂。还提供了包含这些化合物的药物组合物，以及治疗癌症的方法。